Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2019
Price : $35 *
At a glance
- Drugs Vinorelbine (Primary)
- Indications Astrocytoma; Glioma; Oligodendroglioma
- Focus Therapeutic Use
- 28 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 14 Jun 2018 Planned End Date changed from 1 Dec 2019 to 1 Mar 2021.